{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:05:30Z","timestamp":1784905530943,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>The prognostic relevance of IDH1 mutations remains unclear in acute myeloid leukemia (AML). This study, representing the first Turkish AML cohort characterized for IDH1 mutations, aimed to determine the frequency of IDH1, FLT3 and NPM1 mutations and to describe the associated clinical characteristics. We retrospectively analyzed clinical, cytogenetic, and molecular data for 57 AML patients. Bone marrow aspirates were evaluated cytogenetically using G-banding, and molecular mutations were assessed by PCR or NGS (MiSeq-Illumina). IDH1 mutations were detected in 7% of patients; FLT3 and NPM1 mutations were detected in 38.6% and 19.3% of patients, respectively. A significant positive correlation existed between IDH1 and NPM1 mutations (r = 0.388, p = 0.003). Overall mortality was 56.1% and remission was achieved in 43.9%. Older age (p = 0.029) and comorbidities (p = 0.009) were significantly linked to mortality. Mortality was 100% in the four IDH1-mutant patients and significantly higher in NPM1-mutant patients. Overall survival was shorter in IDH1-mutants, although the difference did not reach statistical significance (log-rank p = 0.057). Relapse occurred in 26.3%, rising to 50% in the IDH1-mutated subgroup. In this limited cohort, IDH1-mutant cases were associated with shorter overall survival and higher mortality; however, the small number of IDH1-mutant patients (n = 4) precludes definitive prognostic conclusions. Outcomes in NPM1-mutated patients were also less favorable than typically expected, possibly related to co-occurring IDH1 mutations. These descriptive findings characterize the molecular landscape of AML in an underrepresented Turkish population and may provide a foundation for larger, multicenter studies rather than confirming a prognostic role for these mutations.<\/jats:p>","DOI":"10.3390\/cimb48080752","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:53:26Z","timestamp":1784901206000},"page":"752","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IDH1 Mutations in Acute Myeloid Leukemia: Frequency and Clinical Features in the Context of FLT3 and NPM1 Co-Mutations\u2014A Single-Center Study from Turkey"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-5217","authenticated-orcid":false,"given":"Yunus","family":"Catma","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-5445","authenticated-orcid":false,"given":"Simge","family":"Erdem","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-0646","authenticated-orcid":false,"given":"Aynur","family":"Aday","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Genetics, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-0632","authenticated-orcid":false,"given":"Aysegul","family":"Bayrak Tokac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Genetics, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-5978","authenticated-orcid":false,"given":"Metban","family":"Guzel Mastanzade","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-4052","authenticated-orcid":false,"given":"Murat","family":"Ozbalak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipek","family":"Yonal Hindilerden","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Nuri","family":"Yenerel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliha","family":"Nalcaci","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukru","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Genetics, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Kalayoglu Besisik","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/asheducation-2017.1.37","article-title":"Classification and risk assessment in AML: Integrating cytogenetics and molecular profiling","volume":"2017","author":"Grimwade","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_4","first-page":"630","article-title":"Research progress of isocitrate dehydrogenase mutation-positive acute myeloid leukemia\u2013Review","volume":"32","author":"Ye","year":"2024","journal-title":"Zhongguo Shi Yan Xue YE Xue Za Zhi"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2021-149794","article-title":"Isocitrate dehydrogenase (IDH) 1 and 2 mutation is an independent predictor of better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A study of the ALWP of EBMT","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.31557\/APJCP.2020.21.3.721","article-title":"IDH mutations in AML patients; a higher association with intermediate risk cytogenetics","volume":"21","author":"ElNahass","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-140494","article-title":"AML with isocitrate dehydrogenases (IDH) 1 and 2 mutations: A real-world study from the European IDH Research Group","volume":"136","author":"Maggioni","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ajh.25517","article-title":"The combination of NPM1, DNMT3A, and IDH1\/2 mutations leads to inferior overall survival in AML","volume":"94","author":"Dunlap","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-141229","article-title":"IDH mutations identify a subgroup of NPM1 patients with a more favorable prognosis","volume":"136","author":"Garciaz","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2018-99-118128","article-title":"Clinical characteristics and outcome in IDH1\/2 mutant AML patients: Analysis of 3898 newly diagnosed patients with acute myeloid leukemia","volume":"132","author":"Middeke","year":"2018","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14715\/cmb\/2021.67.3.12","article-title":"Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia","volume":"67","author":"Ismail","year":"2021","journal-title":"Cell. Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2021-148971","article-title":"Longitudinal next generation sequencing reveals the clonal hierarchy of IDH mutated clones and impact on survival in NPM1 mutated AML","volume":"138","author":"Lachowiez","year":"2021","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e40565","DOI":"10.1097\/MD.0000000000040565","article-title":"Acute myeloid leukemia treatment outcomes with isocitrate dehydrogenase mutations: A systematic review and meta-analysis","volume":"103","author":"Qin","year":"2024","journal-title":"Medicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S2152-2650(21)01733-X","article-title":"AML-407: Mutations highly specific for secondary AML are associated with poor outcomes even in patients with NPM1-mutated ELN favorable risk AML","volume":"21","author":"Chan","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1016\/j.clml.2020.07.002","article-title":"Usefulness of Charlson Comorbidity Index to predict early mortality and overall survival in older patients with acute myeloid leukemia","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PPO.0000000000000570","article-title":"Combining isocitrate dehydrogenase inhibitors with existing regimens in acute myeloid leukemia","volume":"28","author":"Lachowiez","year":"2022","journal-title":"Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4274\/tjh.2016.0401","article-title":"TET2, ASXL1, IDH1, and IDH2 single nucleotide polymorphisms in Turkish patients with chronic myeloproliferative neoplasms","volume":"34","author":"Soyer","year":"2017","journal-title":"Turk. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ajh.24113","article-title":"Assessing the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) by analyzing survival endpoints in defined groups of acute myeloid leukemia patients","volume":"90","author":"Grosicki","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bbmt.2018.05.021","article-title":"Validation of the revised Pretransplant Assessment of Mortality Score in patients with acute myelogenous leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Middeke","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.2147\/OTT.S219703","article-title":"Detection of mutations in the isocitrate dehydrogenase genes (IDH1\/IDH2) using castPCR\u2122 in patients with AML and their clinical impact in Mexico City","volume":"12","author":"Olarte","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2023-182012","article-title":"Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions","volume":"142","author":"Chin","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","article-title":"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate-risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood"},{"key":"ref_26","first-page":"2883","article-title":"Clinical outcomes using frontline \u201ctriplet\u201d regimens for IDH1\/2-mutated AML: Results from a pooled analysis of two prospective trials","volume":"144","author":"Atluri","year":"2024","journal-title":"Am. Soc. Hematol. Annu. Meet. Abstr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.HS9.0000565552.28135.de","article-title":"Clinical impact of NPM1 mutation subtypes in a monocentric cohort of acute myeloid leukemia","volume":"3","author":"Fabris","year":"2019","journal-title":"HemaSphere"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4274\/Tjh.2012.0048","article-title":"Prognostic impact of Nucleophosmin 1 (NPM1) gene mutations in Egyptian acute myeloid leukemia patients","volume":"30","author":"Zidan","year":"2013","journal-title":"Turk. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: A COG, SWOG, and ECOG analysis","volume":"7","author":"Alonzo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V122.21.831.831","article-title":"Heterogeneity of patients with cytogenetically normal acute myeloid leukemia (CN-AML) and Nucleophosmin-1 (NPM1) gene mutation: An Acute Leukemia French Association (ALFA) study","volume":"122","author":"Peterlin","year":"2013","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e27458","DOI":"10.1097\/MD.0000000000027458","article-title":"Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study","volume":"100","author":"Merdin","year":"2021","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2478\/bjmg-2020-0024","article-title":"Two novel CEBPA mutations in a Turkish patient with acute myeloid leukemia","volume":"23","author":"Tokgun","year":"2021","journal-title":"Balk. J. Med. Genet."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/8\/752\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:21:38Z","timestamp":1784902898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/8\/752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cimb48080752"],"URL":"https:\/\/doi.org\/10.3390\/cimb48080752","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}